Gilead Stock News

Gilead Sciences (NASDAQ: GILD ) has outperformed the market over the past 20 years by 6.58% on an annualized basis. Buying $100 In GILD: 20 years ago, an investor could have purchased 21.39 shares of Gilead Sciences at the time with $100. This investment in GILD would have produced an average … Full story available on Benzinga.com

Gilead (GILD) has struggled for a number of years and the 5-year annualized total return is 0.6% per year.

The "Metastatic Colorectal cancer - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com''s offering. The publisher''s, "Metastatic Colorectal cancer - Pipeline Insight, 2022," report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in Metastatic Colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. A detailed picture of the Metastatic Colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

Questioning the recent clinical data submitted by the company for its breast cancer therapy Trodelvy, Barclays has trimmed the price target of Gilead Sciences <> on Thursday by…

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

Gilead Sciences, Inc. (GILD) Presents at Cowen Annual Health Care Conference (Transcript)

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results

Gilead Sciences, Inc. (GILD) Management Presents at Raymond James 43rd Annual Institutional Investors Conference (Transcript)

While Gilead's (GILD) phase III study evaluating Trodelvy in late-line HR+/HER- breast cancer did achieve its primary endpoint, the lack of numerical data puts ambiguity on the significance of results

Gilead Sciences <> is trading lower on Monday even after the company announced that its late-stage trial for Trodelvy met the primary endpoint in certain patients with…

Gilead Sciences Inc (NASDAQ: GILD ) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer. The trial included breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors, and two to four lines of chemotherapy. The study met its primary endpoint with a statistically significant improvement in progression-free survival … Full story available on Benzinga.com